Views: 1,523 | Downloads:
21
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Buserelin Acetate Implants in the Treatment of Pain in Endometriosis
Choktanasiri W 
,
Rojanasaku A
,
Rojanasaku A WICHARN CHOKTANASIRI, M.D.*,
ARAM ROJANASAKUL, M.D.*
Objective : To examine the treatment of pain m endometriosis by buserelin acetate
implants.
Design : Fourteen patients with laparoscopically confirmed pelvic endometriosis were
included in the study. All presented with severe dysmenorrhea with or without deep dyspareunia
and pelvic pain. Buserelin acetate 6.6 mg. Implants were injected subcutaneously in the lateral
region of the anterior abdominal wall, 3 doses every 8 weeks in group 1 (n=7) and 2 doses
every 12 weeks in group 2 (n=7). Bone mineral density (BMD) was measured at the lumbar
spine by dual energy X-ray absorptiometry (DEXA) before initiation of treatment and 1 year
after. Symptoms, pelvic examination, ultrasonogram and serum estradiol were recorded every
4 weeks until two regular menses were established.
Results : All the painful symptoms were relieved and eventually disappeared in every
patient within 4-6 weeks. Mean duration of amenorrhea in group 1 (408.4เธ‘47.7 days) was signi-
ficantly longer than group 2 (331.3เธ‘22.4 days), p
<
0.0 1. Mean duration of first observed side
effects was 2.7เธ‘1.6 weeks. Hot flushes were the most common side effects. Serum estradiol
levels were below 15 pg/ml in all patients and there were no significant differences between
the two groups during amenorrhea. There was significant bone loss in both groups, 6.49เธ‘4.90
per cent in group I and 7.71เธ‘5.67 per cent in group 2. However, there were no significant
differences between the two groups for lumbar BMD before and after treatment.
Conclusion : Buserelin acetate implants are effective in the treatment of pain in endo-
metriosis. These implants should have an important clinical application when chronic treatment is
indicated. Further study is needed to design how this preparation should be used to minimize
the adverse effects.
Key word : Endometriosis, Buserelin Acetate Implants
ARAM ROJANASAKUL, M.D.*
Objective : To examine the treatment of pain m endometriosis by buserelin acetate
implants.
Design : Fourteen patients with laparoscopically confirmed pelvic endometriosis were
included in the study. All presented with severe dysmenorrhea with or without deep dyspareunia
and pelvic pain. Buserelin acetate 6.6 mg. Implants were injected subcutaneously in the lateral
region of the anterior abdominal wall, 3 doses every 8 weeks in group 1 (n=7) and 2 doses
every 12 weeks in group 2 (n=7). Bone mineral density (BMD) was measured at the lumbar
spine by dual energy X-ray absorptiometry (DEXA) before initiation of treatment and 1 year
after. Symptoms, pelvic examination, ultrasonogram and serum estradiol were recorded every
4 weeks until two regular menses were established.
Results : All the painful symptoms were relieved and eventually disappeared in every
patient within 4-6 weeks. Mean duration of amenorrhea in group 1 (408.4เธ‘47.7 days) was signi-
ficantly longer than group 2 (331.3เธ‘22.4 days), p
<
0.0 1. Mean duration of first observed side
effects was 2.7เธ‘1.6 weeks. Hot flushes were the most common side effects. Serum estradiol
levels were below 15 pg/ml in all patients and there were no significant differences between
the two groups during amenorrhea. There was significant bone loss in both groups, 6.49เธ‘4.90
per cent in group I and 7.71เธ‘5.67 per cent in group 2. However, there were no significant
differences between the two groups for lumbar BMD before and after treatment.
Conclusion : Buserelin acetate implants are effective in the treatment of pain in endo-
metriosis. These implants should have an important clinical application when chronic treatment is
indicated. Further study is needed to design how this preparation should be used to minimize
the adverse effects.
Key word : Endometriosis, Buserelin Acetate Implants
Download:
PDF